首页
订购/客服:400-666-5481

3-arylisoquinolinamine derivative

    
≥99%

3-arylisoquinolinamine derivative

源叶(MedMol)
S81735 一键复制产品信息
1029008-71-6
C18H19N3O
293.3629
1,2,4-Oxadiazole,3-(3-methoxyphenyl)-5-phenyl; 3-(3-methoxyphenyl)-N7,N7-dimethylisoquinoline-1,7-diamine;
货号 规格 价格 上海 北京 珠海 重庆 武汉 购买数量
S81735-5mg
≥99%

¥880.00

货期:3-5天 - - - -
S81735-10mg
≥99%

¥1480.00

货期:3-5天 - - - -
S81735-50mg
≥99%

¥5180.00

货期:3-5天 - - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品
产品描述: 3-arylisoquinolinamine derivative is a 3-arylisoquinolinamine derivative with antitumor activity.
靶点: IC50: 21 nM (breast MDA-MB-231), 19 nM (pancreas PANC-1), 17 nM (colon HCT 116), 19 nM (prostate PC3), 14 nM (ovary OVCAR-3), 32 nM (melanoma SK-MEL-28), 22 nM (kidney Caki-1), 32 nM (glioblastoma SNB19);Others
体外研究: 3-arylisoquinolinamine derivative is a 3-arylisoquinolinamine derivative, extracted from the reference, compound 7b.3-arylisoquinolinamine derivative (7b) shows more effective activity against Paclitaxel-resistant HCT-15 human colorectal cancer cell lines when compared to the original cytotoxic cancer drug, Paclitaxel. The cell cycle dynamics is analyzed by flow cytometry. Treatment of human HCT-15 cells with 3-arylisoquinolinamine derivative (7b) blocks or delays the progression of cells from G0/G1 phase into S phase, and induces cell death. Treatment with 3-arylisoquinolinamine derivative (7b) also significantly inhibits the growth of tumors and enhances tumor regression in a Paclitaxel-resistant HCT-15 xenograft model. 3-arylisoquinolinamine derivative (7b) inhibits the cell growth at IC50 value ranges from 14 nM to 32 nM in the human cancer cells tested. In cell cycle analysis using HCT-15 cells, treatment of 1 nM of 3-arylisoquinolinamine derivative (7b) displays a significant increase in G0/G1 phase at 24 h with a decrease in G2/M phase, but the increase of G0/G1 phase at 48 h is not significant. At higher concentration of 3-arylisoquinolinamine derivative (7b) (10 nM), there are a significant increase in G0/G1 phase and decrease in G2/M phase, and an emergence of sub-G1phase, at both 24 h and 48 h. 3-arylisoquinolinamine derivative (7b) blocks or delays the progression of cells from G0/G1 phase into S phase, and induces cell death. 3-arylisoquinolinamine derivative is a 3-arylisoquinolinamine
体内研究: 3-arylisoquinolinamine derivative (Compound 13) has higher antitumor efficacy (69.2 % inhibition) than that of the control drug, Paclitaxel (48.8 % inhibition) in the inhibition of growth of tumor in an animal model
参考文献: 1. Yang SH, et al. Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5277-81. 2. Young Bok Lee, et al. 5, 6, or 7-substituted-s- (hetero)arylisoquinolinamine derivatives as antitumor agents. WO 2008063548 A2.
溶解性: soluble  in  DMSO
保存条件: -20℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 3.409 ml 17.044 ml 34.087 ml
5 mM 0.682 ml 3.409 ml 6.817 ml
10 mM 0.341 ml 1.704 ml 3.409 ml
50 mM 0.068 ml 0.341 ml 0.682 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×